Could Having Your DNA Tested Land You in Court?
By Claire Maldarelli,
Popular Science
| 10. 16. 2015
Untitled Document
The story of filmmaker Michael Usry’s arrest seems like it could have come straight from an episode of CSI. A New Orleans-based filmmaker known for his violent, murder-centered films, he was suspected of the 1996 murder of a young woman in Idaho Falls, Idaho. In early 2015, using DNA his father submitted to a private genetics company owned by Ancestry.com, police narrowed down on the filmmaker. Usry submitted his DNA to authorities and when it didn't match, he was found innocent. However, as Wired reports in an article today, the method the cops used to narrow down on Usry--employing private genetics companies' databases to find a suspect--brings to the forefront the already heightened concerns over the use and privacy laws of commercial DNA testing through companies such as Ancestry and 23andMe.
Back in 1996, a suspect was convicted of the murder soon after it took place. However, amid concerns that the wrong man was convicted, the police turned to a controversial technique known as familial searching, which searches a DNA database to look for close...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...